Caitong International Asset Management’s Denali Therapeutics DNLI Stock Holding History
Bought
Maintained
Sold
Other funds holding DNLI
Caitong International Asset Management's DNLI Position: Q2 2026 in Review
Caitong International Asset Management reduced its Denali Therapeutics (DNLI) stake by 100% in Q2 2026, selling an estimated $325K and leaving 46 shares worth $1.18K. The position accounts for ﹤0.01% of the portfolio, ranked #1501.
Caitong International Asset Management first reported a position in DNLI in Q4 2024 and has held it in 6 quarters since. The position peaked at $305K in Q1 2026. 292 funds tracked by Wall St. Rank hold DNLI as of Q2 2026.
- Caitong International Asset Management held 46 shares of Denali Therapeutics worth $1.18K as of Q2 2026.
- Caitong International Asset Management sold 15,815 Denali Therapeutics shares in Q2 2026, an estimated $325K.
- Denali Therapeutics made up ﹤0.01% of Caitong International Asset Management's portfolio in Q2 2026, its #1501 holding.
- Caitong International Asset Management first reported a position in Denali Therapeutics in Q4 2024 and has held it in 6 quarters since.
- Caitong International Asset Management's Denali Therapeutics position peaked at $305K in Q1 2026.
- 292 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2026.
Based on Caitong International Asset Management's 13F filing for Q2 2026, filed 5 Aug 2026.